FERM domain-containing protein 6 (FRMD6)

FRMD6 (FERM domain-containing protein 6), also known as Willin and expanded homolog, is a 622 amino-acid cytoskeletal protein characterized by a FERM domain at the N-terminus and is a key regulator of cell polarity, adhesion, and the Hippo signaling pathway[1][2][4][5]. Its FERM domain mediates interactions with transmembrane proteins and the plasma membrane, allowing it to influence cell junctions and membrane domain size[2][3]. FRMD6 activates Hippo pathway kinases MST and LATS, thereby antagonizing the oncogenic YAP transcriptional regulator and promoting cellular senescence and tumor suppression[1]. FRMD6 expression is upregulated during cellular senescence and in aging tissues, and its gene has been implicated in neurodegeneration and cognitive impairment in clinical studies[2]. It is mainly localized at cell junctions, cytoplasm, and plasma membrane and displays conserved expression across vertebrates[2][4][5]. While FRMD6 is being studied as a biomarker and therapeutic target in cancer, fibrosis, and neurodegenerative diseases, clinical interventions targeting FRMD6 have not yet been developed[1][2][5]. If you require more specific gene, protein, or pathway data, these can be retrieved from authoritative databases such as UniProt, GeneCards, and NCBI Gene[4][5].

Other names

WillinExpanded homologC14orf31MGC17921EX1c14_5320

No approved drugs act on FRMD6; mechanisms would theoretically involve modulation of Hippo pathway signaling and cellular senescence if developed.